⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14676292 | 0.98 | — | — | |
| SCHEMBL4593285 | 0.77 | — | — | |
| SCHEMBL4140175 | 0.77 | — | — | |
| SCHEMBL31234843 | 0.75 | — | — | |
| SCHEMBL7222724 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL29077454 | 0.75 | — | — | |
| SCHEMBL19260901 | 0.75 | — | — | |
| SCHEMBL27570510 | 0.75 | — | — | |
| SCHEMBL2705118 | 0.73 | — | — | |
| SCHEMBL27999850 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115590-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12215096-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4335499-A2 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | Foresee Pharmaceuticals USA, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-3793992-B1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA INC (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023151575-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4192831-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20210214340-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2021-07-15 | — | — | US | disclosed |
| EP-3793992-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | Foresee Pharmaceuticals USA, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-112424186-A | Matrix Metalloproteinase (MMP) inhibitors and methods of use thereof | 逸达生物科技美国公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20190352288-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS CO., LTD (TW) | 2019-11-21 | — | — | US | disclosed |
| WO-2007120102-A1 | NEW SUBSTITUTED OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |